731. Pharmacokinetics of Gepotidacin (GSK2140944) in Subjects with Hepatic Impairment

BACKGROUND: Gepotidacin (GEP), a first in class novel triazaacenaphthylene bacterial topoisomerase inhibitor, inhibits bacterial replication and has in vitro and in vivo efficacy activity against key pathogens, including drug-resistant strains, associated with a range of infections. In a previous ab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Hands, Jonathan T, Tao, Yu, Tiffany, Courtney, Perry, Caroline R, Dumont, Etienne, Hossain, Mohammad
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810886/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.799
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky